Patents by Inventor Lynette A. Fouser

Lynette A. Fouser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8906375
    Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: December 9, 2014
    Assignee: Wyeth LLC
    Inventors: Lynette A. Fouser, Martin Hegen, Deborah P. Luxenberg, Margot O'Toole
  • Patent number: 8470993
    Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: June 25, 2013
    Assignees: Wyeth LLC, MedImmune Limited
    Inventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralph R. Minter
  • Publication number: 20130005033
    Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.
    Type: Application
    Filed: May 22, 2012
    Publication date: January 3, 2013
    Applicants: Wyeth LLC, MedImmune Limited
    Inventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralf R. Minter
  • Patent number: 8187603
    Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.
    Type: Grant
    Filed: May 29, 2009
    Date of Patent: May 29, 2012
    Assignees: Wyeth LLC, MedImmune Limited
    Inventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralph R. Minter
  • Patent number: 8182817
    Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: May 22, 2012
    Assignees: Wyeth LLC, Medimmune Limited
    Inventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralph R. Minter
  • Publication number: 20110212099
    Abstract: The present application provides methods of modulating immune responses by using IL-22 in combination with at least one of IL-17A, IL-17F, or IL-23 or by using an IL-22 antagonist, such as an antibody or a soluble receptor or a binding protein, in combination with an antagonist of at least one of IL-17A, IL-17F, or IL-23
    Type: Application
    Filed: March 15, 2011
    Publication date: September 1, 2011
    Applicant: Wyeth LLC
    Inventors: Spencer C. LIANG, Lynette A. Fouser, Margot O'Toole
  • Publication number: 20110091478
    Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.
    Type: Application
    Filed: November 22, 2010
    Publication date: April 21, 2011
    Applicant: Wyeth LLC
    Inventors: Lynette A. Fouser, Martin Hegen, Deborah P. Luxenberg, Margot O'Toole
  • Patent number: 7901684
    Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.
    Type: Grant
    Filed: February 20, 2007
    Date of Patent: March 8, 2011
    Assignees: Wyeth LLC, Medimmune Limited
    Inventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralph R. Minter
  • Patent number: 7811567
    Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.
    Type: Grant
    Filed: February 20, 2007
    Date of Patent: October 12, 2010
    Assignee: Wyeth LLC
    Inventors: Lynette A. Fouser, Martin Hegen, Deborah P. Luxenberg, Margot O'Toole
  • Publication number: 20100184960
    Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.
    Type: Application
    Filed: January 29, 2010
    Publication date: July 22, 2010
    Applicants: Wyeth, MedImmune Limited
    Inventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralph R. Minter
  • Publication number: 20100015162
    Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.
    Type: Application
    Filed: May 29, 2009
    Publication date: January 21, 2010
    Applicant: Wyeth
    Inventors: Lynette A. FOUSER, Martin Hegen, Deborah P. Luxenberg, Margot O'Toole